Latest episode
15. I wanted to create a healthcare fund that everyone can invest in
01:24:15||Season 1, Ep. 15Years before becoming an expert healthcare investor, a young Claus Henrik Johansen was sitting at his office desk, slightly bored. From the adjacent room he could hear the equity investors at work, shouting and laughing and seemingly having a blast. Then and there, he decided to shift focus from tech and macroeconomics to equity investing in healthcare – and never looked back. Twenty years later, he has his own investment fund; Global Health Invest which he founded and listed on the Nasdaq stock exchange. Tune in as Claus Henrik Johansen tells his story and explains why he had to start his fund, reveals the fundamentals of his investment strategy (and how he sleeps at night) and shares his view on the current market landscape and which global companies he believes will move the needle in the years to come.
More episodes
View all episodes
14. Confessions of a business angel – I listen to Bach and review investment cases
59:38||Season 1, Ep. 14From his childhood venture as a self-employed gardener, to multi-exit entrepreneur and seasoned business angel currently co-raising a 500 MSEK life science fund. Kristofer Klerfalk shares his personal story and insights on being a founder friendly investor, how you review +1000 pitch cases annually (hint: listening to classical music helps!) and the internal checklist he uses to spot a great investment opportunity.
13. On leadership, breaking new ground and Calliditas billion dollar exit
59:29||Season 1, Ep. 13A conversation with Calliditas former CEO Renée Aguiar-Lucander on leadership, courage and transitioning from an early career in the male-dominated world of international finance and investment banking, to breaking new ground as a life science leader on a challenging but rewarding journey towards a multi-billion dollar sale of the company.
12. The best years in venture capital overlap perfectly with big crises
01:15:57||Season 1, Ep. 12Søren Lemonius, founder and managing partner at Sunstone Life Science Ventures, shares the story of how he and his team initiated the Danish VC firm’s investment strategy that has lead to a number of very successful exits – and to some very costly losses. He also reveals why early-stage deals often yield the best returns (”because you’re selling a multiple of a dream”), explains why venture capital thrives in times of crisis and shares the one major reason for why some investments never materialise. We ponder the concept of longevity and find out what Søren considers to be the next hot areas to invest in, why IPOs are not a prefered exit option for Sunstone’s investments and why venture capital firms usually thrive in times of crisis.
11. Earthquakes, investing in drugs and how to be decent in Venture Capital
01:10:10||Season 1, Ep. 11When Johan Kördel, a seasoned investor and managing partner at Swedish venture capital firm Sound Bioventures, suddenly woke up during an earthquake, he knew exactly what to do, yet he did nothing. Luckily, he lived to tell us the earthquake story, and much more! In this episode of Health & Wealth we talk about the dangers of doing nothing as a leader, the importance of risk management and why a portfolio approach is key when you invest in drug development. We also dive into his best investments (and a truly eye-popping exit!), learn about raising a billion SEK fund during a pandemic (hint: you need skin in the game!) and discuss why some disease areas are not considered lucrative, and why being decent is very cool.
10. Målet: Förändra världen för hundra miljoner
34:20||Season 1, Ep. 10Drivkraften för Philip Siberg, vd på Senzime, är att göra skillnad i hundra miljoner människors liv. Hör honom berätta om varför han bestämt sig för att arbeta för hållbarhet, mänskliga rättigheter och om vikten att sträva mot en vision som är värd att berätta för barnbarnen om!
9. Clinical trials: What to know before you invest
30:05||Season 1, Ep. 9When developing new therapies or medicines, there are many hurdles along the way to reaching the market. If you do, that is. Failure is lurking at every step. A drug candidate must be safe and have efficacy in patients without severe side effects. The risks are significant and so are the costs, but if a project is successful the reward could be enormous. So, how to assess the risks involved correctly? In this episode of Health & Wealth Jesper Prior Larsen from Aixial Group, leading experts at clinical trials, walks us through some of the things you need to be aware of before investing in life science.